Spine BioPharma's Phase III MODEL trial assessing SB-01 for people with CLBP associated with DDD failed to achieve its primary goal.

Hansa Biosciences’ Idefirix (imlifidase) has reduced patients’ antibodies to a level that allows dosing in patients with Duchenne muscular dystrophy (DMD) with Sarepta and Roche’s Elevidys ...

Eli Lilly's Jaypirca met its non-inferiority primary endpoint, trumping Imbruvica in patient overall response rate (ORR).

Lantern Pharma has completed targeted enrolment for its multi-centre Phase II HARMONIC trial of a disulfide small molecule, LP-300.

Eli Lilly’s trial evaluating Mounjaro in reducing cardiovascular risk met its endpoint, though missed analyst expectations.

Cognition Therapeutics’ therapy showed up to a 129% slowing of cognitive decline in mild Alzheimer’s disease patients.

Roche’s Alzheimer’s disease therapy has continued to show benefit for patients after 28 weeks in a long-term extension study.

Recognify Life Sciences has reported that its Phase IIb trial of inidascamine to treat CIAS failed to achieve its primary goal.

Shares in Celcuity climbed by 233.76% at market open on 28 July after it reported the Phase III breast cancer data.

Eli Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after over three years of treatment.

Filament Health has collaborated with UCL to provide its botanical psilocybin drug candidate, PEX010, for two Phase II research studies.

Windward Bio has launched the Phase II POLARIS trial of the recombinant, fully human monoclonal antibody, WIN378, in individuals with asthma.